Imfinzi
Imfinzi ingredients
| Active ingredient | Strength |
|---|---|
| Durvalumab | 120 mg/2.4mL, 500 mg/10mL |
What Imfinzi is used for
The FDA lists the approved uses on the official label (below). In the EU, durvalumab is approved as Imfinzi for:
Non-Small Cell Lung Cancer (NSCLC)Imfinzi in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by Imfinzi as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements (for selection criteria, see section 5.1). Imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5.1).Imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations. Small Cell Lung Cancer (SCLC)Imfinzi in combination …
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Imfinzi
- Generic name
- Durvalumab
- Made by
- AstraZeneca Pharmaceuticals LP
- Forms
- Injection, Solution
- Given
- Intravenous
- Drug class
- Programmed Death Ligand-1 Blocker
- FDA approval
- Biologic licence (BLA) BLA761069
- On the US market since
- 2017
Official information
- Imfinzi prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Durvalumab)
In India
- Durvalumab: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Imfinzi?
Imfinzi (Durvalumab) is a cancer medicine made by AstraZeneca Pharmaceuticals LP, approved by the US FDA.
What are the ingredients of Imfinzi?
Imfinzi contains Durvalumab (120 mg/2.4mL, 500 mg/10mL).
Is Imfinzi approved in Europe?
The same active substance is approved in the EU as Imfinzi.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA